scholarly journals Colectomia em paciente com câncer de cólon: relato de caso

2020 ◽  
pp. e3523
Author(s):  
Hudson Fernandes Barile ◽  
Yanka Rafaela da Costa Neto Vieira ◽  
Vinícius Francisco Fernandes Rodrigues ◽  
Amanda de Araújo Dias ◽  
Jamile Lopes Helmer
Keyword(s):  

Objetivo: Relatar o caso de um paciente com câncer de cólon, descoberto em um hospital de referência em cirurgia de uma cidade do Estado do Pará. Relato de caso: Masculino, 64 anos, queixa-se de diarreia, astenia e emagrecimento. Ao exame físico, apresentou massa palpável de 15cm e móvel em flanco direito. A tomografia computadorizada de abdome total com contraste evidenciou tumor de cólon ascendente. Colonoscopia apresentou tumoração blastomatosa infiltrativa com estenose luminal em cólon ascendente distal; pólipo séssil no cólon transverso; biopsia apontou adenocarcinoma moderadamente diferenciado. Após análise dos dados, confirmou-se o diagnóstico de câncer de cólon. O paciente foi submetido à hemicolectomia direita ampliada, peritonectomia localizada, linfadenectomia e reconstrução com anastomose íleo-transversa término-lateral em dois planos. A biópsia da peça cirúrgica reveloucólon ascendente com adenocarcinoma tubular moderadamente diferenciado medindo 5,0 cm e infiltrando até o mesocólon. O estadiamento do câncer indicou T3N2M0 e Dukes C. Orientou-se seguimento oncológico semestral. Considerações finais: É fundamental a investigação eabordagem cirúrgica imediata frente às suspeitas neoplásicas dessa natureza, visando reduzir metástases, dado à lentidão dos métodos diagnósticos de um serviço de saúde pública do país.

2001 ◽  
Vol 44 (3) ◽  
pp. 358-363 ◽  
Author(s):  
W. A. Bleeker ◽  
V. M. Hayes ◽  
A. Karrenbeld ◽  
R. M. W. Hofstra ◽  
E. Verlind ◽  
...  

Oncology ◽  
2000 ◽  
Vol 58 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Hany Elsaleh ◽  
Brenda Powell ◽  
Prinya Soontrapornchai ◽  
David Joseph ◽  
Fabrizio Goria ◽  
...  

2006 ◽  
Vol 53 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Dino Tarabar ◽  
Slavica Knezevic-Usaj ◽  
Zoran Petrovic ◽  
Dusan Jovanovic ◽  
Radoje Doder

Purpose: We studied the prognostic value of thymidylate synthase (TS), Epidermal Growth Factor Receptors (EGFR) and Vascular Endothelial Growth Factor (VEGF) expression in primary colon cancer (CC). Patients and Methods : Those three markers were immunohistochemically assessed on tumor sections from 100 patients with CC Dukes C. All patients received the same adjuvant chemotherapy with FU/Leukovocin according to Mayo protocol. Considering the clinical course they were classified in two groups: bad in which all patients progressed and good in which neither progressed during the five year follow up period. Results: TS, EGFR and VEGF were an independent prognostic factor for time to progression (TTP) and overall survival (OS). Findings of at least two maximum expressed investigated markers, significantly increases the risk of progression which influences shorter five year survival, and the single maximum expression does not necessarily have to be a bad prognostic sign. Conclusion: Highest expression of TS, EGFR and VEGF carries prognostic significance with respect to TTP and OS for patients with Dukes C colon cancer.


2004 ◽  
Vol 51 (2) ◽  
pp. 133-137 ◽  
Author(s):  
Zoran Krivokapic ◽  
Goran Barisic ◽  
V. Markovic ◽  
Milos Popovic ◽  
Sladjan Antic ◽  
...  

In the period 1990 - 2002, 1674 patients with colorectal carcinoma were operated in the First Surgical Clinic, Third Department for Colorectal Surgery. In 1264 cases (75,5%) rectal carcinoma was the indication for surgical treatment. Sphincter saving procedures (SSP) were performed in 824 (65,2%), abdominoperineal resections (APR) in 340 (26,9%) and resections of rectum with definitive stoma (Hartmann procedure) in 100 (7,9%) patients. We analyzed 1095 cases where curative SSP or APR were performed. All cases where curative resection was not possible because of liver metastases or inability to excise all macroscopic disease were excluded. In the group of patients where SSP was performed (767 cases), there were 26,6% high colorectal anastomoses (8cm from anal verge), 65,4% with low (4-8cm from anal verge) and 8,0% with intersphincteric coloanal anastomosis (cm from anal verge). Patohistological exam showed 5,3% Dukes A, 53,1% Dukes B, 36,5% Dukes C and 4,9% Dukes D. In the APR group (328 cases) there were 1,5% Dukes A, 32,4% Dukes B, 62,1% Dukes C and 3,5% Dukes D. In this study we analyzed local recurrence and five-year survival in both groups. Recurrence of the disease was registered in 325 (29,6%) out of 1095 patients. Local recurrence was found in 81 (7,4%) patients. In the SSP group recurrence occured in 215 (28,0%) out of 767 curative resections. Local recurrence alone was found in 53 patients (6,9%). SSP group was also divided into two subgroups; in the first group TME was performed and in second transection of mesorectum was carried out. Analyzing local recurrence in these two groups, in the TME group it was 7,6% and in the transection group 5,6%. In the APR group recurrence was registered in 110 (33,5%) out of 328 patients while local recurrence alone was found in 28 (8,5%) cases. Analyzing mortality we found that 234 (21,4%) out of 1095 patients died during follow-up. In the SSP group 154 out of 767 patients (20,1%) died. In the TME group mortality was 21,7% and in the transection group 16,9%. Mortality in the APR group showed that 80 out of 328 (24,4%) patients died during follow-up. Analysis by the Kaplan-Meier?s test shows cumulative survival of 0,69 for all cases. In the SSP group cumulative survival is 0,72 and in the APR group 0,64 with statistically significant difference (p,001). In the TME group cumulative survival is 0,75 and in the transection group 0,72 with statistically significant difference (p,05). We believe that performing SSP should be encouraged whenever it is possible because there is no difference in local recurrence rates and survival compared to APR. Transection of mesorectum can safely be performed in most cases with tumors located more than 8 cm form anal verge. We believe that exact preoperative staging and preoperative radiotherapy could improve results.


1999 ◽  
Vol 17 (11) ◽  
pp. 3553-3559 ◽  
Author(s):  
Norman Wolmark ◽  
Howard Rockette ◽  
Eleftherios Mamounas ◽  
Judy Jones ◽  
Sam Wieand ◽  
...  

PURPOSE: To compare the efficacy of leucovorin-modulated fluorouracil (FU+LV) with that of fluorouracil and levamisole (FU+LEV) or with the combination of FU+LV and levamisole (FU+LV+LEV). PATIENTS AND METHODS: Between July 1989 and December 1990, 2,151 patients with Dukes' B (stage II) and Dukes' C (stage III) carcinoma of the colon were entered onto National Surgical Adjuvant Breast and Bowl Project protocol C-04. Patients were randomly assigned to receive FU+LV (weekly regimen), FU + LEV, or the combination of FU+LV+LEV. The average time on study was 86 months. RESULTS: A pairwise comparison between patients treated with FU+LV or FU+LEV disclosed a prolongation in disease-free survival (DFS) in favor of the FU+LV group (65% v 60%; P = .04); there was a small prolongation in overall survival that was of borderline significance (74% v 70%; P = .07). There was no difference in the pairwise comparison between patients who received FU+LV or FU+LV+LEV for either DFS (65% v 64%; P = .67) or overall survival (74% v 73%; P = .99). There was no interaction between Dukes' stage and the effect of treatment. CONCLUSION: In patients with Dukes' B and C carcinoma of the colon, treatment with FU+LV seems to confer a small DFS advantage and a borderline prolongation in overall survival when compared with treatment with FU+LEV. The addition of LEV to FU+LV does not provide any additional benefit over and above that achieved with FU+LV. These findings support the use of adjuvant FU+LV as an acceptable therapeutic standard in patients with Dukes' B and C carcinoma of the colon.


2020 ◽  
Vol 477 (5) ◽  
pp. 705-715
Author(s):  
Ines Beilmann-Lehtonen ◽  
Camilla Böckelman ◽  
Harri Mustonen ◽  
Selja Koskensalo ◽  
Jaana Hagström ◽  
...  

Abstract Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host’s immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node–positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49–0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56–4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.


2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3735-3735 ◽  
Author(s):  
K. Sasaki ◽  
H. Takasaka ◽  
K. Kiriyama ◽  
Y. Inafuku ◽  
T. Yabana ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document